Business
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025\n\n\n1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE)\n\n\nEKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD\n\n\nCompany to host conference call today at 8:30am ET\n\n\n FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated financial statements.\n\n\n“As we enter the next phase of the EKTERLY launch, we are seeing the benefits of disciplined execution and increasing real-world experience with the first and only oral on-demand therapy for HAE,” said Ben Palleiko, CEO of KalVista. “The trend towards high adoption continues, as evidenced by steady underlying demand and increasing utilization from patients seeking the benefits of an oral on-demand option. Internationally, EKTERLY’s early performance in Germany, the recent launch in Japan by our partner Kaken Pharmaceutical and our plans to initiate additional market expansions in 2026, reinforce our confidence in the appeal across global markets. We remain focused on expanding access to EKTERLY worldwide while advancing our pediatric filing in patients aged 2–11 later this year. Together, we believe these efforts position EKTERLY to become the foundational therapy for people living with HAE.”\n\n\nEKTERLY® (sebetralstat) Commercial Progress\n\n\n\nInitiated the US commercial launch of EKTERLY on July 7, 2025, with $49.1 million global net product revenue through December 31, 2025.\n\n\n\nRecorded 1,702 patient start forms, representing almost 20% of the US patient population, and activated 724 unique prescribers in the US through February 28, 2026.\n\n\n\nIn the fourth quarter of 2025, the majority of revenue was due to patients receiving refills of EKTERLY.\n\n\n\nGerman launc...